These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24032610)

  • 1. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis.
    Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71(2):117-20. PubMed ID: 24032610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
    J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
    Pincus T; Swearingen CJ; Bergman M; Yazici Y
    J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.
    Pincus T; Yazici Y; Bergman MJ
    Rheum Dis Clin North Am; 2009 Nov; 35(4):773-8, viii. PubMed ID: 19962621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores.
    Yazici Y; Bergman M; Pincus T
    J Rheumatol; 2008 Apr; 35(4):603-9. PubMed ID: 18322993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds.
    Pincus T; Swearingen CJ; Bergman MJ; Colglazier CL; Kaell AT; Kunath AM; Siegel EL; Yazici Y
    Arthritis Care Res (Hoboken); 2010 Feb; 62(2):181-9. PubMed ID: 20191516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis.
    Castrejón I; Bergman MJ; Pincus T
    J Clin Rheumatol; 2013 Jun; 19(4):169-74. PubMed ID: 23669797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based approach to laboratory tests in usual care of patients with rheumatoid arthritis.
    Pincus T; Gibson KA; Shmerling RH
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-23-8. PubMed ID: 25365085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care.
    Pincus T; Yazici Y; Castrejón I
    Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():30-6. PubMed ID: 23259656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
    Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
    J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis.
    Castrejón I; Yazici Y; Pincus T
    Arthritis Care Res (Hoboken); 2013 Feb; 65(2):288-93. PubMed ID: 22807473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ).
    Pincus T; Castrejón I
    Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():14-20. PubMed ID: 23259653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.